Amgen Inc (AMGN) revenue by segment
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 17/3023% above fair value
$443.89−14.04 (-3.07%)
Close on Nov 18, 2026Market cap $239.98BP/E 25.7Yield 2.18%
Doanh thu theo bộ phận của Amgen Inc
Theo bộ phận kinh doanh
Theo sản phẩm hoặc dịch vụ
| Doanh thu | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % doanh thu | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product sales | $35.15B | $32.03B | $26.91B | $24.80B | $24.30B | $24.24B | $22.20B | $22.53B | $21.80B | $21.89B | 95.6% | +9.7% |
| Other products | $7.26B | $5.63B | $4.70B | $5.05B | $5.71B | $5.37B | $4.74B | $5.57B | $2.58B | $3.16B | 19.8% | +29.0% |
| Prolia | $4.41B | $4.37B | $4.05B | $3.63B | $3.25B | $2.76B | $2.67B | $2.29B | $1.97B | $1.64B | 12.0% | +0.9% |
| Repatha | $3.02B | $2.22B | $1.64B | $1.30B | $1.12B | $887.00M | $661.00M | $550.00M | $319.00M | $141.00M | 8.2% | +35.7% |
| Otezla | $2.27B | $2.13B | $2.19B | $2.29B | $2.25B | $2.20B | $178.00M | $0 | – | – | 6.2% | +6.5% |
| ENBREL | $2.23B | $3.32B | $3.70B | $4.12B | $4.47B | $5.00B | $5.23B | $5.01B | $5.43B | $5.97B | 6.1% | -32.9% |
| EVENITY | $2.10B | $1.56B | $1.16B | $787.00M | $530.00M | $350.00M | – | – | – | – | 5.7% | +34.4% |
| XGEVA | $2.08B | $2.23B | $2.11B | $2.01B | $2.02B | $1.90B | $1.94B | $1.79B | $1.58B | $1.53B | 5.7% | -6.3% |
| TEPEZZA | $1.90B | $1.85B | $448.00M | $0 | $0 | – | – | – | – | – | 5.2% | +2.8% |
| Other revenues | $1.60B | $1.40B | $1.28B | $1.52B | $1.68B | $1.18B | $1.16B | $1.21B | $1.05B | $1.10B | 4.4% | +14.7% |
| BLINCYTO | $1.56B | $1.22B | $861.00M | $583.00M | $472.00M | – | – | – | $175.00M | $115.00M | 4.2% | +28.2% |
| Nplate | $1.52B | $1.46B | $1.48B | $1.31B | $1.03B | $850.00M | $795.00M | – | $642.00M | $584.00M | 4.1% | +4.7% |
| TEZSPIRE | $1.48B | $972.00M | $567.00M | $170.00M | – | – | – | – | – | – | 4.0% | +52.1% |
| KYPROLIS | $1.41B | $1.50B | $1.40B | $1.25B | $1.11B | $1.07B | $1.04B | $968.00M | $835.00M | $692.00M | 3.8% | -6.1% |
| Aranesp | $1.39B | $1.34B | $1.36B | $1.42B | $1.48B | $1.57B | $1.73B | $1.88B | $2.05B | $2.09B | 3.8% | +3.5% |
| KRYSTEXXA | $1.34B | $1.19B | $272.00M | $0 | $0 | – | – | – | – | – | 3.6% | +13.1% |
| Vectibix | $1.18B | $1.05B | $984.00M | $893.00M | $873.00M | – | – | – | $642.00M | $611.00M | 3.2% | +12.4% |
| Neulasta (pegfilgrastim) | – | – | – | $1.13B | $1.73B | $2.29B | $3.22B | $4.48B | $4.53B | $4.65B | – | – |
| EPOGEN (epoetin alfa) | – | – | – | – | – | – | $867.00M | $1.01B | $1.10B | $1.28B | – | – |
| Sensipar / Mimpara (cinacalcet) | – | – | – | – | – | – | $551.00M | $1.77B | $1.72B | $1.58B | – | – |
| Other | – | – | – | – | – | – | – | – | $256.00M | $250.00M | – | – |
| NEUPOGEN | – | – | – | – | – | – | – | – | $549.00M | $765.00M | – | – |
Theo khu vực
| Doanh thu | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % doanh thu | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $26.42B | $23.86B | $19.81B | $18.60B | $18.19B | $18.50B | $17.22B | $18.36B | $18.03B | $18.33B | 71.9% | +10.7% |
| ROW | $10.33B | $9.56B | $8.38B | $7.73B | $7.79B | $6.93B | $6.14B | $5.39B | $4.82B | $4.67B | 28.1% | +8.1% |
| Rest of the world (ROW) | – | – | – | – | – | – | – | – | $4.82B | $4.67B | – | – |
Lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K, 10-Q của Amgen (XBRL). Số quý 4 bằng cả năm tài chính trừ chín tháng đầu. Tên bộ phận giữ theo cách công ty tự đặt và có thể đổi khi công ty tái cấu trúc. Tab KPI hiện các bộ phận này cạnh chỉ số vận hành của Amgen, kèm đầy đủ lịch sử, biểu đồ và liên kết tới từng hồ sơ.
See a number that looks wrong?